SAVAW Cassava Sciences, Inc. Warrant

100

Health Care [ 12/12 ] | Biotechnology [ 62/74 ]

NASDAQ | Common Stock

Price: $0.03

Increased by 0.00%
Dollar volume (20D): 340.12 K
ADR%: 45.83

Shares float: 0.00
Shares short: 0.00 [N/A%]
Shares outstanding: 0.00

Market cap: N/A
Beta: N/A
Price/earnings: N/A

20D range: 0.03 0.96
50D range: 0.03 7.07
200D range: 0.03 11.02

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.

Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.

Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Quarterly earnings
Annual earnings

Reported date	EPSChange YoY	EstimateSurprise

Quarterly financials
Annual financials

Fiscal ending date	IncomeChange YoY	ProfitChange YoY
Sep 30, 23	-25.65 M -	Decreased by N/A% -
Jun 30, 23	-26.38 M -	Decreased by N/A% -
Mar 31, 23	-24.27 M -	Decreased by N/A% -
Dec 31, 22	-19.13 M -	Decreased by N/A% -